Is tcrt a good buy

Alaunos Therapeutics Inc (TCRT) does not present a strong buying opportunity at this time. Here's why:

1. Financial Performance: The company has reported negative earnings per share (EPS) of -$0.71 for the most recent quarter, indicating a loss in earnings. Additionally, the net profit margin is a staggering -46833.33%, which is extremely poor. This suggests that the company is not profitable and is losing a significant amount of money relative to its revenue.

2. Stock Movement and Analyst Sentiment: The stock has experienced a downward trend, with a recent drop of 1.1% on August 28 and a 3.6% decline on May 21. Wall Street analysts have given the stock a Hold rating, with an average price target of $2.998, which represents a potential upside from the current price. However, the current price is $3.11, which is already above the average price target, indicating that analysts do not see much upside potential.

3. Technical Indicators: The stock's technical position is not favorable. The closing price on September 27, 2024, was $3.11, which is near the resistance level of $3.69. This suggests that the stock is facing a strong selling pressure. Additionally, the stock's 5-day moving average is $3.41, and the 10-day moving average is $3.04, indicating a recent uptrend that may reverse. The Relative Strength Index (RSI) is at 50.66, which does not indicate either overbought or oversold conditions.

4. Market Sentiment: The overall market sentiment towards TCRT is cautious. The company has missed EPS estimates in the past, with a reported EPS of -$55 cents for the fourth quarter of 2023, which was below the analyst estimate of -$45 cents. This history of missing estimates could lead to skepticism among investors about the company's financial forecasting abilities.
5. Recent Developments: TCRT has recently undergone a stock split and listed on LODAS Markets, which could be seen as a positive sign for increased liquidity and market visibility. However, this does not necessarily translate into a strong buying opportunity, as the fundamentals of the company remain weak.

In conclusion, while the stock split and listing on LODAS Markets could be potential positives, the poor financial performance and lack of profitability make TCRT a risky buy. Investors should exercise caution and consider these factors before making an investment decision.